BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9736337)

  • 1. Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site.
    Guo Y; Wu Y; Kong X; Liu Y
    Mol Immunol; 1998 Mar; 35(4):215-25. PubMed ID: 9736337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
    Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
    J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
    Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS
    J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
    Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
    J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
    Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
    Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
    Zheng P; Wu Y; Guo Y; Lee C; Liu Y
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
    Fallarino F; Fields PE; Gajewski TF
    J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
    Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways.
    DiPaolo RJ; Unanue ER
    J Immunol; 2002 Sep; 169(6):2832-6. PubMed ID: 12218093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
    Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of co-stimulation in airway inflammation.
    Djukanovic R
    Clin Exp Allergy; 2000 Jun; 30 Suppl 1():46-50. PubMed ID: 10849475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    Krummel MF; Allison JP
    J Exp Med; 1995 Aug; 182(2):459-65. PubMed ID: 7543139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
    Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
    J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28-independent costimulation of T cells in alloimmune responses.
    Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
    J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses.
    Haspot F; Villemain F; Laflamme G; Coulon F; Olive D; Tiollier J; Soulillou JP; Vanhove B
    Blood; 2002 Mar; 99(6):2228-34. PubMed ID: 11877302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.